

Association of Dopamine Agonist Use With Impulse Control

Archives of Neurology

63, 969

DOI: 10.1001/archneur.63.7.969

Citation Report

#	ARTICLE	IF	CITATIONS
1	Parkinson Disease: An Update. <i>Neurologist</i> , 2004, 10, 185-194.	0.7	29
2	Dopamine receptor agonists linked with impulse control disorders. <i>Reactions Weekly</i> , 2006, &NA;, 4.	0.0	0
3	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2006, 41, 899-904.	1.0	0
5	Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 517-519.	1.9	204
6	Intervening in the neuropsychiatric features of Parkinsonâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 699-710.	2.8	6
7	Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 1089.	4.5	381
8	Rotigotine transdermal patch in the treatment of Parkinsonâ€™s disease and restless legs syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1329-1335.	1.8	9
9	Medication-related impulse control and repetitive behaviors in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2007, 20, 484-492.	3.6	134
11	Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 516-519.	2.2	56
12	Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 466-479.	2.2	49
13	Risk factors for pathologic gambling and other compulsions among Parkinsonâ€™s disease patients taking dopamine agonists. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1178-1181.	1.5	72
15	Community and Long-Term Care Management of Parkinson's Disease in the Elderly. <i>Drugs and Aging</i> , 2007, 24, 663-680.	2.7	9
16	Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 664-672.	2.5	84
17	Etiologic and Phenotypic Similarities between Medication-Induced Syndromes and Courts' Customary Interpretation of Mental Disease in Exculpatory Defenses. <i>Journal of Psychiatry and Law</i> , 2007, 35, 125-146.	0.2	0
19	Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. <i>Movement Disorders</i> , 2007, 22, 590-591.	3.9	68
20	Internet gambling and other pathological gambling in Parkinson's disease: A case series. <i>Movement Disorders</i> , 2007, 22, 591-593.	3.9	27
21	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. <i>Movement Disorders</i> , 2007, 22, 1757-1763.	3.9	246
22	Assessment of psychiatric complications in Parkinson's disease: The SCOPAâ€¦PC. <i>Movement Disorders</i> , 2007, 22, 2221-2228.	3.9	96

#	ARTICLE	IF	CITATIONS
23	Predictors of punning in Parkinson's disease: Results from a questionnaire survey. <i>Movement Disorders</i> , 2007, 22, 2339-2345.	3.9	53
24	Decision-making with explicit and stable rules in mild Alzheimer's disease. <i>Neuropsychologia</i> , 2007, 45, 1632-1641.	1.6	111
25	Management of impulse control disorders in Parkinson's disease. <i>Current Treatment Options in Neurology</i> , 2007, 9, 189-197.	1.8	30
26	Prevalence of Problem and Pathological Gambling in Parkinson's Disease. <i>Journal of Gambling Studies</i> , 2008, 24, 411-422.	1.6	42
27	Single dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsiveness. <i>Psychopharmacology</i> , 2008, 196, 221-232.	3.1	217
28	Dopamine dysregulation syndrome. <i>Journal of Neurology</i> , 2008, 255, 14-18.	3.6	8
29	Parkinson's disease-related disorders in the impulsive-compulsive spectrum. <i>Journal of Neurology</i> , 2008, 255, 48-56.	3.6	64
30	Long-term follow-up of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 75-80.	3.9	213
31	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 411-415.	3.9	131
32	Suicidal and death ideation in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1573-1579.	3.9	106
33	Current Status of Symptomatic Medical Therapy in Parkinson's Disease. <i>Neurotherapeutics</i> , 2008, 5, 164-180.	4.4	40
34	DEVELOPMENT OF A NEW ASSAY FOR EVALUATION OF L-3,4-DIHYDROXYPHENYLALANINE CYTOTOXICITY IN CATALASE-MUTANT ESCHERICHIA COLI. <i>Environmental Toxicology and Chemistry</i> , 2008, 27, 1768.	4.3	0
35	Impulse Control and Related Disorders in Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2008, 1142, 85-107.	3.8	109
36	Advances in the genetics of Parkinson's disease. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 21-34.	6.1	27
37	Reward pathways in Parkinson's disease: Clinical and theoretical implications. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 203-213.	1.8	28
38	The neurobiology and genetics of impulse control disorders: Relationships to drug addictions. <i>Biochemical Pharmacology</i> , 2008, 75, 63-75.	4.4	428
41	Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2008, 22, 563-586.	5.9	79
42	Predictors of impulsivity and reward seeking behavior with dopamine agonists. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 28-32.	2.2	183

#	ARTICLE	IF	CITATIONS
43	Psychosocial issues in young-onset Parkinson's disease: Current research and challenges. Parkinsonism and Related Disorders, 2008, 14, 143-150.	2.2	34
44	Sexual dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 451-456.	2.2	81
45	Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 368-376.	1.9	3,887
48	Adverse Events from the Treatment of Parkinson's Disease. Neurologic Clinics, 2008, 26, 65-83.	1.8	27
49	Is Dopamine Agonist Therapy Associated with Developing Pathological Gambling in Parkinson's Disease Patients?. European Neurology, 2008, 59, 183-186.	1.4	8
50	Cognitive Impairment in Parkinson's Disease and Dementia with Lewy Bodies: A Spectrum of Disease. NeuroSignals, 2008, 16, 24-34.	0.9	46
51	Effects of Potential Agonist-Replacement Therapies for Stimulant Dependence on Inhibitory Control in Cocaine Abusers. American Journal of Drug and Alcohol Abuse, 2008, 34, 293-305.	2.1	16
52	The safety of dopamine agonists in the treatment of Parkinson's disease. Expert Opinion on Drug Safety, 2008, 7, 111-127.	2.4	9
53	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. Archives of Neurology, 2008, 65, 1604-11.	4.5	127
54	The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3181-3189.	4.0	419
55	The Treatment of Early Parkinson's Disease. , 2008, , 49-70.		1
56	Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.		0
57	Impulse-Control Disorders in Parkinson's Disease. CNS Spectrums, 2008, 13, 690-698.	1.2	60
58	Drugs that affect autonomic functions or the extrapyramidal system. Side Effects of Drugs Annual, 2008, , 170-179.	0.6	0
59	D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function. Current Topics in Medicinal Chemistry, 2008, 8, 1068-1088.	2.1	19
60	Impulse Control Disorders and Pathological Gambling in Patients With Parkinson Disease. Neurologist, 2008, 14, 89-99.	0.7	60
61	Update on the use of pramipexole in the treatment of Parkinson's disease. Neuropsychiatric Disease and Treatment, 2008, 4, 337.	2.2	47
62	Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity. PLoS ONE, 2008, 3, e2479.	2.5	134

#	ARTICLE	IF	CITATIONS
63	STEADY-STATE ASSESSMENT OF IMPULSIVE CHOICE IN LEWIS AND FISCHER 344 RATS: BETWEEN-CONDITION DELAY MANIPULATIONS. Journal of the Experimental Analysis of Behavior, 2008, 90, 333-344.	1.1	50
64	Prevalence of hypersexual behavior in Parkinson's disease patients: Not restricted to males and dopamine agonist use. International Journal of General Medicine, 2009, 2, 57.	1.8	22
66	Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction. Current Drug Abuse Reviews, 2009, 2, 11-25.	3.4	69
67	Neuropsychiatry of Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2009, 67, 930-939.	0.8	35
68	Reward networks in the brain as captured by connectivity measures. Frontiers in Neuroscience, 2009, 3, 350-362.	2.8	96
69	Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgraduate Medical Journal, 2009, 85, 590-596.	1.8	48
70	The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology, 2009, 72, S1-136.	1.1	685
71	Treatment of Early Parkinson's Disease. European Neurology, 2009, 61, 193-205.	1.4	11
72	Treatment of Early Parkinson's Disease. European Neurology, 2009, 61, 206-215.	1.4	12
73	When and how should treatment be started in Parkinson disease?. Neurology, 2009, 72, S39-43.	1.1	52
74	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain, 2009, 132, 1376-1385.	7.6	475
75	Serotonergic and Dopaminergic Modulation of Gambling Behavior as Assessed Using a Novel Rat Gambling Task. Neuropsychopharmacology, 2009, 34, 2329-2343.	5.4	306
76	Decision making under risk and under ambiguity in Parkinson's disease. Neuropsychologia, 2009, 47, 1901-1908.	1.6	65
77	Increased Frequency and Range of Sexual Behavior in a Patient with Parkinson's Disease After Use of Pramipexole: A Case Report. Journal of Sexual Medicine, 2009, 6, 1177-1180.	0.6	33
78	Dopaminergic and serotonergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. Brain Research, 2009, 1265, 196-204.	2.2	72
79	A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurology, The, 2009, 8, 929-937.	10.2	169
80	Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurology, The, 2009, 8, 1140-1149.	10.2	337
81	Dopamine and impulse control disorders in Parkinson's disease. Annals of Neurology, 2008, 64, S93-S100.	5.3	120

#	ARTICLE	IF	CITATIONS
82	Psychotic and compulsive symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 738-744.	3.9	33
83	Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 899-905.	3.9	94
84	Serotonin and Parkinson's disease: On movement, mood, and madness. <i>Movement Disorders</i> , 2009, 24, 1255-1266.	3.9	146
85	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1561-1570.	3.9	192
86	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1461-1467.	3.9	394
87	Association of <i>DRD3</i> and <i>GRIN2B</i> with impulse control and related behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1803-1810.	3.9	148
88	Validity of a self-rated method to identify a lifetime history of depression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2436-2438.	3.9	2
89	Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. <i>Movement Disorders</i> , 2009, 24, 2430-2431.	3.9	19
90	Do autonomic function tests in people with Parkinson's disease predict survival rates at 7 years follow-up?. <i>Movement Disorders</i> , 2009, 24, 2432-2434.	3.9	10
91	Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology. <i>Movement Disorders</i> , 2009, 24, 2316-2327.	3.9	32
92	Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine. <i>Movement Disorders</i> , 2009, 24, 2431-2432.	3.9	0
93	Pramipexole and gender identity disorder: Expanding the phenotype of hypersexuality in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2434-2435.	3.9	8
94	Identification of a novel THAP1 mutation at R29 amino-acid residue in sporadic patients with early-onset dystonia. <i>Movement Disorders</i> , 2009, 24, 2428-2429.	3.9	32
95	Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations. <i>Movement Disorders</i> , 2009, 24, 2442-2443.	3.9	10
96	HIV-associated parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy. <i>Movement Disorders</i> , 2009, 24, 2441-2442.	3.9	12
97	Subacute dopa-responsive parkinsonism after successful surgical treatment of aqueductal stenosis. <i>Movement Disorders</i> , 2009, 24, 2438-2440.	3.9	8
98	Subthalamic deep brain stimulation and impulse control in Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 493-497.	3.3	179
99	Personality, Addiction, Dopamine: Insights from Parkinson's Disease. <i>Neuron</i> , 2009, 61, 502-510.	8.1	313

#	ARTICLE	IF	CITATIONS
100	Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 2009, 16, 1148-1152.	1.5	220
101	Impulse control disorders in Parkinson's disease in a Chinese population. Neuroscience Letters, 2009, 465, 6-9.	2.1	75
102	Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson's Disease. Drug Safety, 2009, 32, 475-488.	3.2	80
105	Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease. Mayo Clinic Proceedings, 2009, 84, 310-316.	3.0	55
106	What do clinical trials tell us about treating patients?. Parkinsonism and Related Disorders, 2009, 15, S34-S37.	2.2	11
107	Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. Parkinsonism and Related Disorders, 2009, 15, S110-S113.	2.2	75
108	Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists. Parkinsonism and Related Disorders, 2009, 15, S71-S75.	2.2	21
109	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism and Related Disorders, 2009, 15, S111-S115.	2.2	101
110	Pathologic Gambling: Biological and Clinical Considerations. Journal of Addiction Medicine, 2009, 3, 111-119.	2.6	14
111	Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behavioural Pharmacology, 2009, 20, 363-379.	1.7	57
112	Impulse Control Disorders Arising in 3 Patients Treated With Rotigotine. Clinical Neuropharmacology, 2009, 32, 59-62.	0.7	30
113	Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. Behavioural Pharmacology, 2009, 20, 492-504.	1.7	24
114	Cognitive and Personality Features in Parkinson Disease: 2 Sides of the Same Coin?. Cognitive and Behavioral Neurology, 2009, 22, 258-263.	0.9	27
115	Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease. Mayo Clinic Proceedings, 2009, 84, 310-316.	3.0	167
116	Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. International Journal of Neuropsychopharmacology, 2010, 13, 549.	2.1	12
117	Outcomes of Patients with Parkinson Disease and Pathological Gambling. Canadian Journal of Neurological Sciences, 2010, 37, 473-477.	0.5	19
118	Impulse Control Disorder and Piribedil. Clinical Neuropharmacology, 2010, 33, 11-13.	0.7	16
119	ETHICAL PERSPECTIVES IN NEUROLOGY. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 166-169.	0.8	0

#	ARTICLE	IF	CITATIONS
120	Drugs that affect autonomic functions or the extrapyramidal system. Side Effects of Drugs Annual, 2010, 32, 281-294.	0.6	0
121	Effects of pramipexole on impulsive choice in male wistar rats.. Experimental and Clinical Psychopharmacology, 2010, 18, 267-276.	1.8	33
122	Impulse Control Disorders with the use of Dopaminergic Agents in Restless Legs Syndrome: a Case-Control Study. Sleep, 2010, , .	1.1	57
123	Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology, 2010, 207, 645-659.	3.1	184
124	Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. Journal of Neurology, 2010, 257, 276-283.	3.6	38
125	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurology, The, 2010, 9, 1200-1213.	10.2	753
126	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology, 2010, 68, 963-968.	5.3	132
127	New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Movement Disorders, 2010, 25, S104-9.	3.9	39
128	The nonmotor symptoms of Parkinson's disease—An overview. Movement Disorders, 2010, 25, S123-30.	3.9	130
129	Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Movement Disorders, 2010, 25, 1660-1669.	3.9	138
130	Dopamine release in ventral striatum of pathological gamblers losing money. Acta Psychiatrica Scandinavica, 2010, 122, 326-333.	4.5	105
131	Insights into pathophysiology of punning reveal possible treatment strategies. Molecular Psychiatry, 2010, 15, 560-573.	7.9	83
132	School problems and suicide in Japanese young people. Psychiatry and Clinical Neurosciences, 2010, 64, 214-215.	1.8	2
133	Skin picking in Parkinson's disease: A behavioral side-effect of dopaminergic treatment?. Psychiatry and Clinical Neurosciences, 2010, 64, 214-214.	1.8	11
134	PRECLINICAL STUDY: FULL ARTICLE: The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addiction Biology, 2010, 15, 312-323.	2.6	46
135	Impulse Control Disorders in Parkinson Disease. Archives of Neurology, 2010, 67, 589-95.	4.5	1,244
136	Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. Archives of Neurology, 2010, 67, 58-63.	4.5	299
137	Dopamine, Reward, and Frontostriatal Circuitry in Impulse Control Disorders in Parkinson's Disease: Insights from Functional Imaging. Clinical EEG and Neuroscience, 2010, 41, 87-93.	1.7	29

#	ARTICLE	IF	CITATIONS
138	Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. International Journal of Impotence Research, 2010, 22, 325-335.	1.8	24
139	Therapy of the Motor Features of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 252-272.	0.1	1
140	Psychiatric Issues in Parkinson's Disease. Blue Books of Neurology, 2010, 34, 213-228.	0.1	3
141	Compulsive Behaviors in Patients With Parkinson's Disease. Neurologist, 2010, 16, 192-195.	0.7	20
142	Hot Water Epilepsy. Neurologist, 2010, 16, 407.	0.7	0
143	Detection of Impulse Control Disorders in Parkinson Disease Patients. Neurologist, 2010, 16, 406-407.	0.7	14
144	Cognitive-behavioral therapy for psychogenic nonepileptic seizures. Neurology, 2010, 74, 1986-1994.	1.1	384
145	Pathological Gambling and Substance Use Disorders. American Journal of Drug and Alcohol Abuse, 2010, 36, 242-247.	2.1	118
146	Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain, 2010, 133, 3611-3624.	7.6	148
147	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.5	10
148	Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. Journal of the Neurological Sciences, 2010, 289, 55-59.	0.6	88
149	Compulsive habits in restless legs syndrome patients under dopaminergic treatment. Journal of the Neurological Sciences, 2010, 290, 52-56.	0.6	56
150	Introduction to Behavioral Addictions. American Journal of Drug and Alcohol Abuse, 2010, 36, 233-241.	2.1	860
151	Long-Term Efficacy of Rasagiline in Early Parkinson's Disease. International Journal of Neuroscience, 2010, 120, 404-408.	1.6	29
152	Decision-making during gambling: an integration of cognitive and psychobiological approaches. Philosophical Transactions of the Royal Society B: Biological Sciences, 2010, 365, 319-330.	4.0	215
153	Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. Journal of Clinical Neuroscience, 2010, 17, 539-540.	1.5	29
154	Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism and Related Disorders, 2010, 16, 202-207.	2.2	161
155	Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism and Related Disorders, 2010, 16, 334-337.	2.2	40

#	ARTICLE	IF	CITATIONS
156	Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors. <i>Neuron</i> , 2010, 65, 135-142.	8.1	259
157	Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism. <i>Neuroscience</i> , 2010, 168, 477-486.	2.3	28
158	A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2010, 11, 512-519.	1.6	91
159	Shared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint?. <i>Annals of the New York Academy of Sciences</i> , 2010, 1187, 294-315.	3.8	161
160	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. <i>Progress in Brain Research</i> , 2010, 184, 177-192.	1.4	21
161	Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. <i>Brain</i> , 2011, 134, 36-49.	7.6	187
163	Iowa Gambling Task in Parkinson's Disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 395-409.	1.3	39
164	Impulsive and compulsive behaviors in Parkinson's disease: A one-year follow-up study. <i>Journal of the Neurological Sciences</i> , 2011, 310, 197-201.	0.6	31
165	Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 183-188.	0.6	42
166	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. <i>Journal of the Neurological Sciences</i> , 2011, 310, 64-69.	0.6	70
167	Disordered Gambling: Etiology, Trajectory, and Clinical Considerations. <i>Annual Review of Clinical Psychology</i> , 2011, 7, 483-510.	12.3	97
168	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
170	The Roles of Dopamine and Serotonin in Decision Making: Evidence from Pharmacological Experiments in Humans. <i>Neuropsychopharmacology</i> , 2011, 36, 114-132.	5.4	192
171	Impulse control disorders and dopaminergic treatments in Parkinson's disease. <i>Revue Neurologique</i> , 2011, 167, 827-832.	1.5	6
172	Dianas quir�rgicas en el tratamiento de enfermedades psiqui�tricas. Desde el movimiento a las emociones. <i>Neurocirug�a</i> , 2011, 22, 5-22.	0.4	6
173	Impulse control disorders in Parkinson's disease: clinical characteristics and implications. <i>Neuropsychiatry</i> , 2011, 1, 133-147.	0.4	31
174	Cognitive enhancement by drugs in health and disease. <i>Trends in Cognitive Sciences</i> , 2011, 15, 28-36.	7.8	223
175	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 153-155.	2.2	61

#	ARTICLE	IF	CITATIONS
176	Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 295-296.	2.2	10
177	Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: A review. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 413-417.	2.2	118
178	Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 379-381.	2.2	36
179	Impulse control disorders in Chinese Parkinson's disease patients: The effect of ergot derived dopamine agonist. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 635-637.	2.2	30
180	Impulsive Behavior and Associated Clinical Variables in Parkinson's Disease. <i>Psychosomatics</i> , 2011, 52, 41-47.	2.5	6
182	Advances in Drug Therapy: Alternative Treatments for the Control of Motor Fluctuations and Dyskinesias. , 0, , .		0
183	Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-6.	1.1	33
184	Impulse Control Disorders Following Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: Clinical Aspects. <i>Parkinson's Disease</i> , 2011, 2011, 1-9.	1.1	38
185	Available and emerging treatments for Parkinson's disease: a review. <i>Drug Design, Development and Therapy</i> , 2011, 5, 241.	4.3	34
186	Modulation of Habit Formation by Levodopa in Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e27695.	2.5	4
187	Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and/or anxiety. <i>Behavioural Pharmacology</i> , 2011, 22, 711-713.	1.7	40
189	Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. <i>Addiction</i> , 2011, 106, 283-293.	3.3	79
190	Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. <i>Neuropsychologia</i> , 2011, 49, 103-107.	1.6	18
191	Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson's Disease. <i>Experimental Neurology</i> , 2011, 231, 181-189.	4.1	25
192	Pathological gambling in Parkinson's disease: disease related or drug related?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 809-814.	2.8	7
193	An Eight Component Decision-Making Model for Problem Gambling:A Systems Approach to Stimulate Integrative Research. <i>Journal of Gambling Studies</i> , 2011, 27, 523-563.	1.6	20
194	Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. <i>Experimental Brain Research</i> , 2011, 213, 435-445.	1.5	68
195	Drug-Induced Impulse Control Disorders: A Prospectus for Neuroethical Analysis. <i>Neuroethics</i> , 2011, 4, 91-102.	2.8	19

#	ARTICLE	IF	CITATIONS
196	Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurology, 2011, 11, 117.	1.8	107
197	Twiceâ€daily, lowâ€dose pramipexole in early Parkinson's disease: A randomized, placeboâ€controlled trial. Movement Disorders, 2011, 26, 37-44.	3.9	44
198	Impulsivity and compulsivity in drugâ€naïve patients with Parkinson's disease. Movement Disorders, 2011, 26, 464-468.	3.9	139
199	Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. Movement Disorders, 2011, 26, 830-836.	3.9	104
200	Parkinson's disease: The quintessential neuropsychiatric disorder. Movement Disorders, 2011, 26, 1022-1031.	3.9	349
201	Reward processing abnormalities in Parkinson's disease. Movement Disorders, 2011, 26, 1451-1457.	3.9	38
202	Intertemporal choice in Parkinson's disease. Movement Disorders, 2011, 26, 2004-2010.	3.9	66
203	The <i>Movement</i> Disorder Society Evidenceâ€Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Movement Disorders, 2011, 26, S2-41.	3.9	479
204	Pramipexole modulates the neural network of reward anticipation. Human Brain Mapping, 2011, 32, 800-811.	3.6	86
205	A<sub>2A</sub> Adenosine Receptor Binding Parameters in Platelets from Patients Affected by Pathological Gambling. Neuropsychobiology, 2011, 63, 154-159.	1.9	1
206	Nonmotor problems in Parkinson disease. , 2011, , 183-196.		0
207	Possible Sites of Therapeutic Action in Restless Legs Syndrome: Focus on Dopamine and Î±<sub>2</sub> Ligands. European Neurology, 2011, 66, 18-29.	1.4	29
208	The risky business of dopamine agonists in Parkinson disease and impulse control disorders.. Behavioral Neuroscience, 2011, 125, 492-500.	1.2	92
209	Management of sexual dysfunction in Parkinsonâ€™s disease. Therapeutic Advances in Neurological Disorders, 2011, 4, 375-383.	3.5	91
210	Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights. International Journal of Neuroscience, 2011, 121, 45-52.	1.6	18
211	Dose-Dependent Impulse Control Disorders in Piribedil Overdose. Clinical Neuropharmacology, 2012, 35, 49-50.	0.7	13
212	Comparison of Personality Characteristics in Parkinson Disease Patients With and Without Impulse Control Disorders and in Healthy Volunteers. Cognitive and Behavioral Neurology, 2012, 25, 25-33.	0.9	16
213	Impulsive and Compulsive Behaviors During Dopamine Replacement Treatment in Parkinsonâ€™s Disease and Other Disorders. Current Drug Safety, 2012, 7, 63-75.	0.6	43

#	ARTICLE	IF	CITATIONS
214	Impulse control disorders in Parkinson's disease: background and update on prevention and management. <i>Neurodegenerative Disease Management</i> , 2012, 2, 389-400.	2.2	10
215	VUV Photoionization and Dissociation of Tyramine and Dopamine: the Joint Experimental and Theoretical Studies. <i>Chinese Journal of Chemical Physics</i> , 2012, 25, 11-18.	1.3	5
216	Exploring Hypersexual Behavior in Men with Parkinson's Disease: Is it Compulsive Sexual Behavior?. <i>Journal of Parkinson's Disease</i> , 2012, 2, 225-234.	2.8	13
217	Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 23-41.	3.5	22
218	The temptation of suicide: striatal gray matter, discounting of delayed rewards, and suicide attempts in late-life depression. <i>Psychological Medicine</i> , 2012, 42, 1203-1215.	4.5	170
219	Deep Brain Stimulation and Behavioural Changes: Is Comedication the Most Important Factor?. <i>Neurodegenerative Diseases</i> , 2012, 9, 18-24.	1.4	10
220	Pathological Gambling: A Systematic Review of Biochemical, Neuroimaging, and Neuropsychological Findings. <i>Harvard Review of Psychiatry</i> , 2012, 20, 130-148.	2.1	84
221	A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach. <i>Journal of Neurology</i> , 2012, 259, 2299-2308.	3.6	28
222	Long-term use of pramipexole in the management of restless legs syndrome. <i>Sleep Medicine</i> , 2012, 13, 1280-1285.	1.6	103
223	Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 10-16.	2.2	39
224	Prescribing in Parkinson's disease: a story of hope and adverse events. <i>Practical Neurology</i> , 2012, 12, 335-340.	1.1	14
225	An update on the management of juvenile and young-onset Parkinson's disease. <i>Future Neurology</i> , 2012, 7, 581-593.	0.5	1
226	Is premature ejaculation an impulse control disorder?. <i>Medical Hypotheses</i> , 2012, 79, 59-62.	1.5	5
227	A case of multiple system atrophy with normal dopamine transporter imaging. <i>Journal of Neurology</i> , 2012, 259, 2729-2731.	3.6	6
228	Neuroplasticity and impulse control disorders. <i>Journal of the Neurological Sciences</i> , 2012, 316, 15-20.	0.6	5
230	Addictive behaviors and Parkinson's disease. <i>Revue Neurologique</i> , 2012, 168, 624-633.	1.5	26
231	A Combination of Dopamine Genes Predicts Success by Professional Wall Street Traders. <i>PLoS ONE</i> , 2012, 7, e30844.	2.5	24
232	Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects. <i>Parkinson's Disease</i> , 2012, 2012, 1-15.	1.1	79

#	ARTICLE	IF	CITATIONS
233	Epidemiology of Psychiatric Symptoms in Parkinson's Disease. Advances in Biological Psychiatry, 2012, , 1-12.	0.2	5
234	The Neuropsychopharmacology of Pathological Gambling. Current Psychiatry Reviews, 2012, 8, 20-24.	0.9	3
236	Dopamine Agonists and the Suppression of Impulsive Motor Actions in Parkinson Disease. Journal of Cognitive Neuroscience, 2012, 24, 1709-1724.	2.3	66
237	Dysexecutive Syndrome. Cognitive and Behavioral Neurology, 2012, 25, 57-62.	0.9	14
238	Addiction and Parkinson's Disease. , 2012, , 363-374.		0
239	ADDICTION AS ABERRANT LEARNINGâ€”EVIDENCE FROM PARKINSON'S DISEASE. Addiction, 2012, 107, 248-250.	3.3	3
240	Compulsive buying in bipolar disorder: Is it a comorbidity or a complication?. Journal of Affective Disorders, 2012, 136, 797-802.	4.1	22
241	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurology, The, 2012, 11, 429-442.	10.2	343
242	Dose dependent dopaminergic modulation of reward-based learning in Parkinson's disease. Neuropsychologia, 2012, 50, 583-591.	1.6	15
243	Are there ethnic differences in impulsive/compulsive behaviors in Parkinson's disease?. European Journal of Neurology, 2012, 19, 494-500.	3.3	29
244	Perceptions of cause and control of impulse control behaviours in people with Parkinson's disease. British Journal of Health Psychology, 2012, 17, 522-535.	3.5	11
245	Questionnaire for impulsiveâ€”compulsive disorders in Parkinson's Diseaseâ€”Rating Scale. Movement Disorders, 2012, 27, 242-247.	3.9	263
247	Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task. Psychopharmacology, 2013, 225, 719-731.	3.1	90
248	Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. Journal of Neurology, 2013, 260, 429-437.	3.6	27
249	Dopamine Agonist-Induced Impulse Control Disorders in a Patient with Prolactinoma. Psychosomatics, 2013, 54, 387-391.	2.5	16
250	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain, 2013, 136, 400-411.	7.6	172
251	Reward Signals, Attempted Suicide, and Impulsivity in Late-Life Depression. JAMA Psychiatry, 2013, 70, 1020.	11.0	200
252	Rasagiline adjunct therapy in patients with Parkinson's disease: Post-hoc analyses of the PRESTO and LARGO trials. Parkinsonism and Related Disorders, 2013, 19, 930-936.	2.2	29

#	ARTICLE	IF	CITATIONS
253	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Reviews in the Neurosciences, 2013, 24, 267-78.	2.9	152
254	Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. Journal of Clinical Neuroscience, 2013, 20, 964-969.	1.5	40
255	A Systematic Review of Impulse Control Disorders in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 105-138.	2.8	118
256	Subthalamic stimulation modulates self-estimation of patients with Parkinson's disease and induces risk-seeking behaviour. Brain, 2013, 136, 3271-3281.	7.6	30
257	Diagnosis and treatment of impulse control disorders in patients with movement disorders. Therapeutic Advances in Neurological Disorders, 2013, 6, 175-188.	3.5	29
258	Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 698-700.	2.2	44
259	Inhibitory Effects of Pergolide and Cabergoline Formulations on Daily Plasma Prolactin Concentrations in Geldings and on the Daily Prolactin Responses to a Small Dose of Sulpiride in Mares. Journal of Equine Veterinary Science, 2013, 33, 773-778.	0.9	9
260	Prospective cohort study of impulse control disorders in Parkinson's disease. Movement Disorders, 2013, 28, 327-333.	3.9	136
261	Pathological gambling in Parkinson's disease. A comprehensive review. Parkinsonism and Related Disorders, 2013, 19, 645-653.	2.2	67
262	Handbook of Parkinson's Disease. , 2013, , .		14
263	Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive/Compulsive Disorders in Parkinson's disease. Journal of the Neurological Sciences, 2013, 331, 76-80.	0.6	32
264	Initial Treatment of Parkinson's Disease: An Update. Current Treatment Options in Neurology, 2013, 15, 377-384.	1.8	5
265	Pramipexole-Induced Obsessive-Compulsive Symptoms in a Patient with Parkinson's Disease and Disgust Sensitivity. Psychosomatics, 2013, 54, 286-289.	2.5	3
266	Sleep and impulsivity in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 991-994.	2.2	37
267	Managing impulse control behaviours in Parkinson's disease: practical guidelines. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 160-166.	0.5	14
268	The Role of Self-Awareness and Cognitive Dysfunction in Parkinson's Disease With and Without Impulse-Control Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2013, 25, 141-149.	1.8	29
270	Impulse Control Disorder in a Patient on Long-Term Treatment With Bromocriptine for a Macroprolactinoma. Clinical Neuropharmacology, 2013, 36, 170-172.	0.7	15
271	Impulsivity and apathy in Parkinson's disease. Journal of Neuropsychology, 2013, 7, 255-283.	1.4	81

#	ARTICLE	IF	CITATIONS
272	Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 139-144.	2.8	39
274	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
275	The Iowa Gambling Task and the three fallacies of dopamine in gambling disorder. <i>Frontiers in Psychology</i> , 2013, 4, 709.	2.1	17
276	Dopaminergic and Clinical Correlates of Pathological Gambling in Parkinson's Disease: A Case Report. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 95.	2.0	10
277	How central is dopamine to pathological gambling or gambling disorder?. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 206.	2.0	91
278	Neural and behavioral substrates of subtypes of Parkinson's disease. <i>Frontiers in Systems Neuroscience</i> , 2013, 7, 117.	2.5	24
279	Impulse Control Disorders in Parkinson's Disease: Crossroads between Neurology, Psychiatry and Neuroscience. <i>Behavioural Neurology</i> , 2013, 27, 547-557.	2.1	12
280	An update on the management of young-onset Parkinson's disease. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2013, 2, 53.	1.3	2
281	Multiple Modes of Impulsivity in Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e85747.	2.5	116
282	Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1093.	2.2	20
283	Impulsive and Compulsive Behaviors in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 318.	3.4	31
284	Ventral striatal dopamine synthesis capacity is associated with individual differences in behavioral disinhibition. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 86.	2.0	19
285	The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 196.	2.0	43
286	Maladaptive Reward-Learning and Impulse Control Disorders in Patients with Parkinson's Disease: A Clinical Overview and Pathophysiology Update. <i>Journal of Movement Disorders</i> , 2014, 7, 67-76.	1.3	10
287	Gambling Disorder during Dopamine Replacement Treatment in Parkinson's Disease: A Comprehensive Review. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	19
288	Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients. <i>Neuropsychopharmacology</i> , 2014, 39, 274-282.	5.4	33
289	Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP). <i>Annals of Indian Academy of Neurology</i> , 2014, 18, 49-59.	0.5	33
290	Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1028-1034.	3.9	44

#	ARTICLE	IF	CITATIONS
291	Motor impulsivity in Parkinson disease: Associations with <scp>COMT</scp> and <scp>DRD</scp>2 polymorphisms. Scandinavian Journal of Psychology, 2014, 55, 278-286.	1.5	17
292	Treating Compulsive Buying Disorder. Current Treatment Options in Psychiatry, 2014, 1, 315-324.	1.9	5
293	Understanding Parkinson disease. Nurse Practitioner, 2014, 39, 1-10.	0.3	3
294	Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 840-844.	1.9	200
295	The Contribution of Apathy and Increased Learning Trials to Risky Decision-Making in Parkinson's Disease. Archives of Clinical Neuropsychology, 2014, 29, 100-109.	0.5	22
296	Pharmacological Treatment of Parkinson Disease. JAMA - Journal of the American Medical Association, 2014, 311, 1670.	7.4	1,097
297	Eating Disorders, Addictions and Substance Use Disorders. , 2014, , .		9
298	Rasagiline induced hypersexuality in Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2014, 21, 507-508.	1.5	21
299	Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary, 2014, 17, 150-156.	2.9	53
300	Anhedonia in Parkinson's disease patients with and without pathological gambling: A case-control study. Psychiatry Research, 2014, 215, 448-452.	3.3	81
301	Impulse control disorders in patients with dopamine agonistâ€™treated prolactinomas and nonfunctioning pituitary adenomas: a caseâ€™control study. Clinical Endocrinology, 2014, 80, 863-868.	2.4	103
302	Impulse Control Disorders in Parkinson's Disease Are Associated with Dysfunction in Stimulus Valuation But Not Action Valuation. Journal of Neuroscience, 2014, 34, 7814-7824.	3.6	73
303	Impulse control and repetitive behaviors in Parkinson's disease â€™ Are there differences in the relation to dopamine agonist treatment?. Journal of the Neurological Sciences, 2014, 345, 252-253.	0.6	1
304	Study protocol: the JEU cohort study â€™ transversal multiaxial evaluation and 5-year follow-up of a cohort of French gamblers. BMC Psychiatry, 2014, 14, 226.	2.6	16
306	Targeting impulsivity in Parkinsonâ€™s disease using atomoxetine. Brain, 2014, 137, 1986-1997.	7.6	116
307	Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 23-30.	1.9	42
308	Enhanced creative thinking under dopaminergic therapy in Parkinson disease. Annals of Neurology, 2014, 75, 935-942.	5.3	57
309	Brain circuitry of compulsivity and impulsivity. CNS Spectrums, 2014, 19, 21-27.	1.2	52

#	ARTICLE	IF	CITATIONS
310	Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration's Adverse Event database. <i>Journal of Behavioral Addictions</i> , 2014, 3, 21-26.	3.7	9
311	Intertemporal choice in Parkinson's disease and restless legs syndrome. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1330-1335.	2.2	26
312	Translational Models of Gambling-Related Decision-Making. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 93-120.	1.7	32
313	Compulsive Masturbation With Pramipexole for Antidepressant Augmentation in Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 485.	1.4	2
314	Doping for Chess Performance. , 2015, 05, .		1
315	Nonmotor symptoms in Parkinson's disease: classification and management. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2015, , 1.	0.8	5
316	Social behavioral changes in MPTP-treated monkey model of Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 42.	2.0	17
317	Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 49.	2.0	151
318	Multifaceted effects of noisy galvanic vestibular stimulation on manual tracking behavior in Parkinson's disease. <i>Frontiers in Systems Neuroscience</i> , 2015, 9, 5.	2.5	29
319	Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome – patient considerations. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2015, 5, 63.	1.3	2
320	Piribedil and Pathological Gambling in six Parkinsonian patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 115-118.	0.8	11
321	Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 130, 297-323.	1.8	38
322	Fiber grating compression of giant-chirped nanosecond pulses from an ultra-long nanotube mode-locked fiber laser. <i>Optics Letters</i> , 2015, 40, 387.	3.3	28
323	A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson's disease. <i>Psychiatry Research</i> , 2015, 225, 402-406.	3.3	12
324	Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. <i>Synapse</i> , 2015, 69, 183-189.	1.2	123
326	Does Response Inhibition Have Pre- and Postdiagnostic Utility in Parkinson's Disease?. <i>Journal of Motor Behavior</i> , 2015, 47, 29-45.	0.9	12
327	Pet Killing as a Manifestation of Impulse Control Disorder Secondary to Pramipexol. <i>Clinical Neuropharmacology</i> , 2015, 38, 55-56.	0.7	12
328	International validation of a behavioral scale in Parkinson's disease without dementia. <i>Movement Disorders</i> , 2015, 30, 705-713.	3.9	88

#	ARTICLE	IF	CITATIONS
329	Behavioral effects of levodopa. Movement Disorders, 2015, 30, 90-102.	3.9	63
330	Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. Pharmacology Biochemistry and Behavior, 2015, 129, 19-25.	2.9	43
331	Clinical spectrum of impulse control disorders in Parkinson's disease. Movement Disorders, 2015, 30, 121-127.	3.9	264
332	Improving Response Inhibition in Parkinson's Disease with Atomoxetine. Biological Psychiatry, 2015, 77, 740-748.	1.3	93
333	Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. Journal of Neurology, 2015, 262, 7-20.	3.6	20
334	Dopaminergic Medication in Parkinson's Disease and Problem Gambling. Journal of Gambling Studies, 2015, 31, 1085-1106.	1.6	9
335	Reward-based decision making in pathological gambling: The roles of risk and delay. Neuroscience Research, 2015, 90, 3-14.	1.9	96
336	Impact of Sex on the Nonmotor Symptoms and the Health-Related Quality of Life in Parkinson's Disease. Parkinson's Disease, 2016, 2016, 1-12.	1.1	43
337	Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers. Frontiers in Human Neuroscience, 2016, 10, 523.	2.0	8
338	Neuropsychiatric Symptoms in Parkinson's Disease: Beyond Complications. Frontiers in Psychiatry, 2016, 7, 110.	2.6	17
339	Introduction to Parkinson disease (PD) and its complications. Mental Health Clinician, 2016, 6, 229-235.	1.0	9
341	Human behavioral assessments in current research of Parkinson's disease. Neuroscience and Biobehavioral Reviews, 2016, 68, 741-772.	6.1	58
342	Management of impulse control disorders in Parkinson's disease. International Psychogeriatrics, 2016, 28, 1597-1614.	1.0	16
343	Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease. Neurologia (English Edition), 2016, 31, 231-238.	0.4	15
344	Dissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease. Journal of Cognitive Neuroscience, 2016, 28, 710-723.	2.3	37
345	How close are we to individualized medicine for Parkinson's disease?. Expert Review of Neurotherapeutics, 2016, 16, 815-830.	2.8	21
346	Brainjacking: Implant Security Issues in Invasive Neuromodulation. World Neurosurgery, 2016, 92, 454-462.	1.3	95
347	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. European Journal of Neurology, 2016, 23, 1556-1565.	3.3	51

#	ARTICLE	IF	CITATIONS
348	Impulse control disorders in Parkinson's disease: Predominant role of psychological determinants. <i>Psychology and Health</i> , 2016, 31, 1391-1414.	2.2	10
349	Neuropsychiatric manifestations of Parkinson's disease. <i>Australasian Psychiatry</i> , 2016, 24, 529-533.	0.7	8
350	Long-term safety and effectiveness of pramipexole in tetrahydrobiopterin deficiency. <i>European Journal of Paediatric Neurology</i> , 2016, 20, 839-842.	1.6	14
351	Advances in dopamine receptor agonists for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1889-1902.	1.8	37
352	Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 267-277.	2.8	28
353	A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2016, 30, 957-966.	4.0	1
354	The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. <i>Journal of the Neurological Sciences</i> , 2016, 368, 150-154.	0.6	115
355	Behavioral and Pharmacological Treatment of Compulsive Sexual Behavior/Problematic Hypersexuality. <i>Current Addiction Reports</i> , 2016, 3, 406-413.	3.4	4
357	COMT and ANKK1 Genetics Interact With Depression to Influence Behavior Following Severe TBI. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 920-930.	2.9	32
358	Dopamine D ₃ Receptors Modulate the Ability of Win-Paired Cues to Increase Risky Choice in a Rat Gambling Task. <i>Journal of Neuroscience</i> , 2016, 36, 785-794.	3.6	76
359	A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 181-198.	2.4	30
360	Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 63-70.	1.4	38
361	Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease. <i>Neuropsychopharmacology</i> , 2016, 41, 2171-2177.	5.4	43
362	Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 389-399.	2.8	22
363	The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 10-16.	2.2	48
364	A survey of impulse control disorders in Parkinson's disease patients in Shanghai area and literature review. <i>Translational Neurodegeneration</i> , 2016, 5, 4.	8.0	15
365	Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity. <i>Journal of the Neurological Sciences</i> , 2016, 362, 344-347.	0.6	22
367	Dopamine Selectively Modulates the Outcome of Learning Unnatural Action-Valence Associations. <i>Journal of Cognitive Neuroscience</i> , 2017, 29, 816-826.	2.3	8

#	ARTICLE	IF	CITATIONS
368	Focused stimulation of dorsal subthalamic nucleus improves reactive inhibitory control of action impulses. <i>Neuropsychologia</i> , 2017, 99, 37-47.	1.6	37
369	Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study. <i>Journal of Parkinson's Disease</i> , 2017, 7, 183-191.	2.8	48
370	Possible Role of Serotonin and Selective Serotonin Reuptake Inhibitors in Suicidal Ideations and Attempts. <i>Journal of Pharmaceutical Sciences and Pharmacology</i> , 2017, 3, 54-70.	0.2	2
371	Parkinson Symptoms in Dementia with Lewy Bodies. , 2017, , 93-109.		1
372	Pramipexole Modulates Interregional Connectivity Within the Sensorimotor Network. <i>Brain Connectivity</i> , 2017, 7, 258-263.	1.7	9
374	Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 737-749.	2.8	7
375	A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 783-789.	3.9	27
376	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 317-324.	1.9	119
377	Impulse control disorder, lysosomal malfunction and ATP^{13A2} insufficiency in Parkinsonism. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 172-179.	1.9	4
378	Longitudinal decline of driving safety in Parkinson disease. <i>Neurology</i> , 2017, 89, 1951-1958.	1.1	24
379	Subject-enabled analytics model on measurement statistics in health risk expert system for public health informatics. <i>International Journal of Medical Informatics</i> , 2017, 107, 18-29.	3.3	8
380	Response to Commentaries: Recognizing Hypersexuality as a Psychosexual Behavioral Problem and Advancing the Sexhavior Cycle of Hypersexuality. <i>Archives of Sexual Behavior</i> , 2017, 46, 2279-2287.	1.9	6
382	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 5.	5.3	29
383	Hypersexuality: A Critical Review and Introduction to the "Sexhavior Cycle". <i>Archives of Sexual Behavior</i> , 2017, 46, 2231-2251.	1.9	124
384	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. <i>Cortex</i> , 2017, 94, 63-72.	2.4	53
385	Impulse Control and Related Disorders in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 679-717.	2.0	195
386	Chronic $\text{D}_{2/3}$ agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns. <i>European Journal of Neuroscience</i> , 2017, 45, 159-166.	2.6	34
388	Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?. <i>European Journal of Neuroscience</i> , 2017, 45, 67-72.	2.6	25

#	ARTICLE	IF	CITATIONS
389	Neuropsychiatric symptoms in untreated Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 815-826.	2.2	37
390	Caregiver Burden and the Nonmotor Symptoms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 479-497.	2.0	57
391	Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson's Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 145.	2.0	26
393	Impulse control disorders in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 1299-1312.	2.8	22
394	Independent and Complementary Validation of the QUIP-RS in Advanced Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 341-342.	1.5	3
395	Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease. <i>Neuropsychologia</i> , 2018, 109, 262-269.	1.6	14
396	Lack of Increase in Sexual Drive and Function After Dopaminergic Stimulation in Women. <i>Journal of Sex and Marital Therapy</i> , 2018, 44, 61-72.	1.5	6
397	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 6-13.	1.5	20
398	Motivational Sensitivities Linked to Impulsive Motor Errors in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 128-138.	1.8	6
399	Dopamine Agonists and Impulse Control Disorders: A Complex Association. <i>Drug Safety</i> , 2018, 41, 19-75.	3.2	101
400	Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels. <i>Psychopharmacology</i> , 2018, 235, 23-35.	3.1	12
401	Psychiatric Manifestation in Patients with Parkinson's Disease. <i>Journal of Korean Medical Science</i> , 2018, 33, e300.	2.5	58
402	Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. <i>Frontiers in Neurology</i> , 2018, 9, 1041.	2.4	11
403	An Integrative Biopsychosocial and Sex Positive Model of Understanding and Treatment of Impulsive/Compulsive Sexual Behavior. <i>Sexual Addiction and Compulsivity</i> , 2018, 25, 125-152.	0.9	29
404	Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 365-404.	2.0	0
406	Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease. <i>Brain and Behavior</i> , 2018, 8, e01008.	2.2	16
407	The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. <i>Brain and Behavior</i> , 2018, 8, e01036.	2.2	21
408	Impulsivity in Parkinson's Disease Is Associated With Alterations in Affective and Sensorimotor Striatal Networks. <i>Frontiers in Neurology</i> , 2018, 9, 279.	2.4	26

#	ARTICLE	IF	CITATIONS
409	Impulse-Control Disorders in Parkinsonâ€™s Disease: A Meta-Analysis and Review of Caseâ€“Control Studies. <i>Frontiers in Neurology</i> , 2018, 9, 330.	2.4	39
410	Degenerative Movement Disorders of the Central Nervous System. , 2018, , 321-325.e3.		0
411	Dysfunctional inhibitory control in Parkinsonâ€™s disease patients with levodopa-induced dyskinesias. <i>Journal of Neurology</i> , 2018, 265, 2088-2096.	3.6	23
412	Remote delivery of psychological interventions for Parkinson's disease. <i>International Psychogeriatrics</i> , 2018, 30, 1783-1795.	1.0	76
413	Sleep in Parkinsonâ€™s Disease with Impulse Control Disorder. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 68.	4.2	6
414	Longitudinal analysis of impulse control disorders in Parkinson disease. <i>Neurology</i> , 2018, 91, e189-e201.	1.1	175
415	Awareness and current knowledge of Parkinsonâ€™s disease: a neurodegenerative disorder. <i>International Journal of Neuroscience</i> , 2019, 129, 55-93.	1.6	57
416	Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decisionâ€“making. <i>European Journal of Neuroscience</i> , 2019, 50, 2392-2400.	2.6	7
417	Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. <i>Annals of Neurology</i> , 2019, 86, 762-769.	5.3	29
418	Gambling disorder. <i>Nature Reviews Disease Primers</i> , 2019, 5, 51.	30.5	233
419	Impulse control disorders in Parkinson disease and RBD. <i>Neurology</i> , 2019, 93, e675-e687.	1.1	44
420	Atomoxetine and citalopram alter brain network organization in Parkinsonâ€™s disease. <i>Brain Communications</i> , 2019, 1, fcz013.	3.3	10
421	Risk factors for impulse control disorders and related behaviors in Parkinsonâ€™s disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019, 8, 159-166.	2.2	8
422	Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinsonâ€™s Disease Cohort. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	1.1	4
423	Why would Parkinsonâ€™s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 100, 129-165.	6.1	17
424	Impulse control disorders in Parkinsonâ€™s disease: A systematic review on the psychometric properties of the existing measures. <i>PLoS ONE</i> , 2019, 14, e0217700.	2.5	4
426	Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 707, 134313.	2.1	10
427	Parkinsonâ€™s disease management and impulse control disorders: current state and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 495-508.	2.8	7

#	ARTICLE	IF	CITATIONS
428	Deep Brain Stimulation of the Subthalamic Nucleus Induces Impulsive Responses to Bursts of Sensory Evidence. <i>Frontiers in Neuroscience</i> , 2019, 13, 270.	2.8	2
429	Can Slot-Machine Reward Schedules Induce Gambling Addiction in Rats?. <i>Journal of Gambling Studies</i> , 2019, 35, 887-914.	1.6	5
430	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 998-1018.	1.2	82
431	Creativity related to dopaminergic treatment: A multicenter study. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 169-173.	2.2	10
432	Impulse control disorders in Parkinson's disease: A 20-year odyssey. <i>Movement Disorders</i> , 2019, 34, 447-452.	3.9	26
433	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Diseaseâ€“Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019, 63, 117-123.	2.2	9
434	Impulse Control Disorders in REM Sleep Behavior Disorder. <i>Current Treatment Options in Neurology</i> , 2019, 21, 23.	1.8	7
435	<p>A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1011-1022.	4.3	10
436	Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco. <i>Revue Neurologique</i> , 2019, 175, 233-237.	1.5	22
437	Safety and Tolerability of Pharmacotherapies for Parkinsonâ€™s Disease in Geriatric Patients. <i>Drugs and Aging</i> , 2019, 36, 511-530.	2.7	38
438	Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 86.	2.4	41
439	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. <i>PLoS ONE</i> , 2019, 14, e0210880.	2.5	8
440	Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinsonâ€™s Disease. <i>Neurodegenerative Diseases</i> , 2019, 19, 171-177.	1.4	4
441	About the Misleading Use of Stereodescriptors in Labeling the Stereoisomers of Milnacipran and Levomilnacipran. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 673-674.	1.4	0
442	Parkinson's disease: Diagnosis and appreciation of comorbidities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 257-277.	1.8	7
443	Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 675-676.	1.4	4
444	Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 30-37.	1.9	16
445	Dopaminergic influences on risk preferences of Parkinsonâ€™s disease patients. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2019, 19, 88-97.	2.0	11

#	ARTICLE	IF	CITATIONS
446	Pharmacological insights into impulsive-compulsive spectrum disorders associated with dopaminergic therapy. <i>European Journal of Neuroscience</i> , 2019, 50, 2492-2502.	2.6	9
447	Iowa Gambling Task Performance in Parkinson Disease Patients with Impulse Control Disorders. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 310-318.	0.5	11
448	Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model. <i>Journal of Neuropsychology</i> , 2020, 14, 318-332.	1.4	7
449	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2165-2174.	6.4	5
450	Dopaminergic signaling of uncertainty and the aetiology of gambling addiction. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109853.	4.8	22
451	Management of Urologic and Sexual Dysfunction in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 69-80.	2.6	12
452	Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. <i>Growth Hormone and IGF Research</i> , 2020, 55, 101356.	1.1	6
453	Sexual function and depressive symptoms in young women with hypoprolactinaemia. <i>Clinical Endocrinology</i> , 2020, 93, 482-488.	2.4	10
454	“Dopamine agonist Phobia” in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 953-965.	2.8	7
455	Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2020, 11, 579606.	3.5	19
456	Too much of a good thing: hedonistic homeostatic dysregulation and other behavioural consequences of excessive dopamine replacement therapy in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 566-567.	1.9	2
457	Neurobiology of cue-reactivity, craving, and inhibitory control in non-substance addictive behaviors. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116952.	0.6	72
458	Management of psychiatric disorders in Parkinson's disease. <i>Neurotherapeutics</i> , 2020, 17, 1511-1524.	4.4	19
459	Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 591-598.	1.9	4
461	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. <i>Npj Parkinson's Disease</i> , 2020, 6, 6.	5.3	5
462	Behavioral and Neuroanatomical Account of Impulsivity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1338.	2.4	20
463	The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism. <i>European Neuropsychopharmacology</i> , 2020, 32, 104-119.	0.7	4
464	The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109942.	4.8	25

#	ARTICLE	IF	CITATIONS
465	Measuring impulsivity in Parkinson's disease: a correlational and structural neuroimaging study using different tests. <i>European Journal of Neurology</i> , 2020, 27, 1478-1486.	3.3	6
466	Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 425-435.	1.3	3
467	Personality dimensions of patients can change during the course of parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245142.	2.5	5
468	Cognitive and Behavioral Inhibition Deficits in Parkinson's Disease: The Hayling Test as a Reliable Marker. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 621603.	3.4	7
469	The effect of psychological and medical conditions on sexuality. , 2021, , 195-234.		0
470	Degenerative Movement Disorders of the Central Nervous System. , 2021, , 972-982.		0
471	Sexual Disorders and Quality of Life in Parkinson's Disease. <i>Sexual Medicine</i> , 2021, 9, 100280-100280.	1.6	16
472	Noradrenergic contributions to cue-driven risk-taking and impulsivity. <i>Psychopharmacology</i> , 2021, 238, 1765-1779.	3.1	10
473	Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: A pilot study. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2022, 69, 279-288.	0.3	3
475	Discontinuation of Dopamine Agonists in Parkinson's Disease: A Retrospective Analysis. <i>Osmangaz</i> Journal of Medicine, 0, , .	0.1	0
476	Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1091-1115.	2.8	10
477	The role of dopamine in action control: Insights from medication effects in Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 158-170.	6.1	12
478	Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinson's Disease Population. <i>Healthcare (Switzerland)</i> , 2021, 9, 1263.	2.0	1
479	Editorial Comment: Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1057-1060.	1.5	0
480	3D fuzzy graphene microelectrode array for dopamine sensing at sub-cellular spatial resolution. <i>Biosensors and Bioelectronics</i> , 2021, 191, 113440.	10.1	25
481	Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7.		0
482	Impulse Control Disorders. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , 79-98.	0.3	2
483	DBS Innovations in the Near Future?. , 2019, , 159-172.		1

#	ARTICLE	IF	CITATIONS
485	Neurotoxic Effects of Pharmaceutical Agents III: Neurological Agents. , 2009, , 358-371.		2
486	Depression and Psychosis in Neurological Practice. , 2012, , 92-116.		10
488	Dopaminergic medication improves cognitive control under low cognitive demand in Parkinson's disease.. Neuropsychology, 2020, 34, 551-559.	1.3	3
491	The Emergence of Devastating Impulse Control Disorders During Dopamine Agonist Therapy of the Restless Legs Syndrome. Clinical Neuropharmacology, 2011, 34, 66-70.	0.7	47
492	Binge Eating in Parkinson's Disease: Prevalence, Correlates and the Contribution of Deep Brain Stimulation. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 56-62.	1.8	62
493	Impulsive Cross-Dressing in Parkinson's Disease Treated With Ropinerole. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E8-E8.	1.8	1
496	Deep Brain Stimulation of Nucleus Accumbens Region in Alcoholism Affects Reward Processing. PLoS ONE, 2012, 7, e36572.	2.5	53
497	A Conditioned Response as a Measure of Impulsive-Compulsive Behaviours in Parkinson's Disease. PLoS ONE, 2014, 9, e89319.	2.5	15
498	Identifying the Basal Ganglia Network Model Markers for Medication-Induced Impulsivity in Parkinson's Disease Patients. PLoS ONE, 2015, 10, e0127542.	2.5	20
499	Deep-Brain Stimulation of the Subthalamic Nucleus Selectively Decreases Risky Choice in Risk-Preferring Rats. ENeuro, 2017, 4, ENEURO.0094-17.2017.	1.9	28
500	Subthalamic Neural Activity Patterns Anticipate Economic Risk Decisions in Gambling. ENeuro, 2018, 5, ENEURO.0366-17.2017.	1.9	11
502	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease. Current Pharmaceutical Design, 2020, 26, 509-516.	1.9	9
503	Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. Current Neuropharmacology, 2016, 14, 356-363.	2.9	28
504	Impulse control disorders in Parkinson's disease: crossroads between neurology, psychiatry and neuroscience. Behavioural Neurology, 2013, 27, 547-57.	2.1	8
505	Does the brain prefer geometrical homogeneity?. Behavioural Neurology, 2010, 23, 101-5.	2.1	3
507	Impulse control disorders in Parkinson's disease. F1000 Medicine Reports, 2009, 1, .	2.9	3
508	The treatment of erectile dysfunction in patients with neurogenic disease. Translational Andrology and Urology, 2016, 5, 88-101.	1.4	27
509	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		

#	ARTICLE	IF	CITATIONS
510	Olanzapine in the Treatment of Pathological Gambling. Journal of Clinical Psychiatry, 2008, 69, 433-440.	2.2	140
511	Optogenetics and its application in neural degeneration and regeneration. Neural Regeneration Research, 2017, 12, 1197.	3.0	42
512	ADRs in a Community Hospital â€” Do These Numbers Look like Yours?; A Gagggle of â€œDermatologicâ€• Reactions â€” TEN, Iodide Mumps, Doxycycline Phototoxicity; Pergolide-Induced Ergotism; Acute Coronary Syndrome Due to Fluorouracil Infusion; Aripiprazole-Induced Acute Dystonic Reaction; Meta-Analysis: Cardiovascular Events and NSAIDs; More on Dopamine Agonists and Impulse Control Disorders. Hospital Pharmacy, 2006, 41, 816-904.	1.0	2
514	Entscheiden bei Morbus Parkinson â€” eine Ãœbersicht. Zeitschrift FÃ¼r Neuropsychologie = Journal of Neuropsychology, 2008, 19, 235-251.	0.6	0
515	Current Concepts in the Classification, Treatment, and Modeling of Pathological Gambling and Other Impulse Control Disorders. , 2008, , 317-357.		1
516	Impulse-Control Disorders. , 2008, , 305-317.		0
517	Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease. Yearbook of Neurology and Neurosurgery, 2008, 2008, 75-76.	0.0	0
518	Malattia di Parkinson. , 2009, , 347-369.		1
520	Medical Management of Parkinsonâ€™s Disease. , 2009, , 1507-1527.		0
523	StratÃ©gies mÃ©dicamenteuses antiparkinsoniennes. , 2011, , 155-178.		1
525	BewegungsstÃ¶rungen. , 2011, , 955-1054.		0
529	L-DOPA-Induced Disinhibition in Parkinson Disease: More than Agonistic Behavior. Biological Systems, Open Access, 2012, 02, .	0.1	0
530	Update in Parkinsonâ€™s Disease. , 0, , .		2
531	fMRI in Parkinsonâ€™s Disease. , 2013, , 227-238.		0
532	Dopamine agonists. , 2013, , 414-429.		0
533	How May Neuroscience Affect the Way that the Criminal Courts Deal with Addicted Offenders?. , 2013, , 279-302.		0
534	Relationship of Behavioral Addictions to Eating Disorders and Substance Use Disorders. , 2014, , 405-428.		1
535	Personality Style in Behavioural Disturbances in Parkinson's Disease. Journal of Neurology & Neurophysiology, 2014, 05, .	0.1	1

#	ARTICLE	IF	CITATIONS
536	Addictions comportementales dans la maladie de Parkinson. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 1297-1308.	0.0	0
537	StratÃ©gies mÃ©dicamenteuses. , 2015, , 143-161.e2.		0
539	Prevalence Of Impulse Control Disorders Among Adult Filipino Patients With Idiopathic Parkinsonâ€™s Disease Seen At Jose R. Reyes Memorial Medical Center. Journal of Neurological Research and Therapy, 2015, 1, 13-19.	0.2	1
540	Psychiatric Disorders. , 2016, , 127-138.		0
541	Impulse Control Behavior in Movement Disorders: Focus on Restless Leg Syndrome. , 2017, , 229-244.		0
542	Sex and Pharmacological Sexual Enhancement. , 2017, , 387-411.		0
543	Hypersexuality in Parkinsonâ€™s disease. Aktualnosci Neurologiczne, 2017, 17, 158-161.	0.1	0
544	Macroprolactinoma: Alternatives to Dopamine Agonist Therapy for Treatment of Macroprolactinomas in Patients Who Present with Psychotic Symptoms. , 2018, , 9-20.		0
547	Psychiatric Symptoms Comorbid with Neurological Syndromes. , 2019, , 201-218.		0
548	Parkinsonism and Related Disorders. , 0, , .		0
549	Definition and Classification of Parkinsonian Drugs. , 2020, , 1-30.		0
551	Hypersexuality Due to Adverse Effects of Medicines and Surgical Interventions. Health of Man, 2020, .	0.0	0
552	Intimacy, parkinsonâ€™s disease and dementia in the time of the coronavirus. Archive of Gerontology and Geriatrics Research, 2020, , 029-030.	0.3	0
553	Impulse Control Disorders associated with Pramipexole/Ropinirole Use in Non-Parkinsonâ€™s Disease: A Scoping Review. Korean Journal of Clinical Pharmacy, 2020, 30, 250-258.	0.3	0
554	Dopamine genetic risk score predicts impulse control behaviors in Parkinsonâ€™s disease. Clinical Parkinsonism & Related Disorders, 2021, 5, 100113.	0.9	3
555	Decision-Making and Impulse-Control Disorders in Parkinson's Disease. Neurological Sciences and Neurophysiology, 2020, 37, 11-17.	0.3	0
556	123I-Ioflupane dopamine transporter imaging (DaTSCAN) appearances in relation to emotional responsiveness, impulsivity and olfaction in suspected Parkinsonian syndrome. Nuclear Medicine Communications, 2020, 41, 1117-1127.	1.1	2
558	Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep, 2010, 33, 81-7.	1.1	132

#	ARTICLE	IF	CITATIONS
559	Pramipexole and compulsive masturbation. Psychiatry, 2007, 4, 57-9.	0.3	4
561	Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iranian Journal of Neurology, 2015, 14, 86-93.	0.5	12
562	Parkinson's Disease and Behavioral Addiction: the susceptibilities and risks. Asian Journal of Psychiatry, 2021, 68, 102960.	2.0	0
563	Prevalence, clinical presentations and impact on relationship of sexual dysfunction in Parkinson's Disease. International Review of Neurobiology, 2022, 162, 1-19.	2.0	2
564	The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting. Brain Research Bulletin, 2022, 181, 157-166.	3.0	2
565	Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease. Progress in Brain Research, 2022, 269, 309-343.	1.4	10
566	Impulse control disorders, dopamine dysregulation syndrome and sex dysfunction in Parkinson's disease. International Review of Neurobiology, 2022, 162, 117-134.	2.0	2
567	P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Advances in Therapy, 2022, 39, 1881-1894.	2.9	5
573	Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: A pilot study. Endocrinologia y Diabetes y Nutrición (English Ed), 2022, 69, 279-288.	0.2	4
574	Genetic prediction of impulse control disorders in Parkinson's disease. Annals of Clinical and Translational Neurology, 2022, 9, 936-949.	3.7	15
575	Neural correlates of risky decision making in Parkinson's disease patients with impulse control disorders. Experimental Brain Research, 2022, 240, 2241-2253.	1.5	3
577	Cognitive Behavioral Therapy Plus a Serious Game as a Complementary Tool for a Patient With Parkinson Disease and Impulse Control Disorder: Case Report. JMIR Serious Games, 2022, 10, e33858.	3.1	1
578	Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson's Disease?. Journal of Parkinson's Disease, 2022, 12, 2261-2275.	2.8	2
579	Drug reprofiling history and potential therapies against Parkinson's disease. Frontiers in Pharmacology, 0, 13, .	3.5	2
581	Definition and Classification of Parkinsonian Drugs. , 2022, , 2823-2852.		1
582	Should patients with Parkinson's disease only visit a neurologist's office? - a narrative review of neuropsychiatric disorders among people with Parkinson's disease. Current Problems of Psychiatry, 2022, 23, 220-236.	0.2	0
583	Neural correlates of impulsive compulsive behaviors in Parkinson's disease: A Japanese retrospective study. Neurolmage: Clinical, 2023, 37, 103307.	2.7	1
584	Altered delay discounting in neurodegeneration: insight into the underlying mechanisms and perspectives for clinical applications. Neuroscience and Biobehavioral Reviews, 2023, , 105048.	6.1	2

#	ARTICLE	IF	CITATIONS
585	Quality of life implications for elevated trait impulsivity in people with Parkinson's disease. Quality of Life Research, 2023, 32, 1143-1150.	3.1	1
586	D _{2/3} Agonist during Learning Potentiates Cued Risky Choice. Journal of Neuroscience, 2023, 43, 979-992.	3.6	5
587	Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies. British Journal of Clinical Pharmacology, 2023, 89, 1304-1317.	2.4	2
588	Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. Journal of Neural Transmission, 2023, 130, 125-133.	2.8	1
591	Performance on the balloon analogue risk task and anticipatory response inhibition task is associated with severity of impulse control behaviours in people with Parkinson's disease. Experimental Brain Research, 2023, 241, 1159-1172.	1.5	2
592	Course of Impulse Control Disorder Symptoms in Parkinson's Disease: Deep Brain Stimulation Versus Medications. Movement Disorders Clinical Practice, 2023, 10, 903-913.	1.5	2
593	Edible Bird's Nest: Seeing the Unseen. , 2023, , 115-139.		0
594	Multivariate associations between dopamine receptor availability and risky investment decision-making across adulthood. Cerebral Cortex Communications, 2023, 4, .	1.6	0
595	Impulse control disorder in Parkinson's disease is associated with abnormal frontal value signalling. Brain, 2023, 146, 3676-3689.	7.6	4
596	White matter hyperintensities associated with impulse control disorders in Parkinson's Disease. Scientific Reports, 2023, 13, .	3.3	1
597	Time perception reflects individual differences in motor and non-motor symptoms of Parkinson's disease. Parkinsonism and Related Disorders, 2023, 114, 105800.	2.2	1
598	Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease. European Journal of Neurology, 2024, 31, .	3.3	1
599	Sex differences in risk-based decision-making and the modulation of risk preference by dopamine-2 like receptors in rats. Neuropharmacology, 2024, 248, 109851.	4.1	0
600	Impulse control disorders and its association to medication use and other associated factors in patients with Parkinson's disease. , 0, , .		0